ProPhase Labs, Inc. (PRPH) Key Metrics
PRPH valuation today
Trailing 12 months · as of October 21, 2026- Market cap
- $132,536
- Enterprise value
- $9.3M
- P/E (TTM)
- —
- Forward P/E
- 10.5
- PEG ratio
- —
- Price / sales
- 0.0
- Price / book
- 0.4
- EV / EBITDA
- 2.4
- Dividend yield
- —
- Beta
- 0.14
PRPH key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsPRPH returns How much profit the business earns on the capital it uses.
PRPH financial health Debt, liquidity and how easily interest is covered.
PRPH efficiency & capital use Working capital cycle and where the cash goes.
PRPH valuation history
PRPH returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PRPH debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PRPH cash returned to shareholders
PRPH price vs earnings per share
PRPH key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $3.8M | — | — | — | — | — | — | — | — | — |
| Enterprise value | $12.3M | — | — | — | — | — | — | — | — | — |
| Price / sales | 0.9 | — | — | — | — | — | — | — | — | — |
| Price / book | 1.1 | — | — | — | — | — | — | — | — | — |
| EV / sales | 2.8 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −388.1% | — | — | — | — | — | — | — | — | — |
| Free cash flow yield | −219.6% | — | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $0.45 | $7.57 | $45.20 | $96.30 | $71.70 | $91.80 | $19.70 | $31.50 | $21.70 | $20.00 |
| Per share | ||||||||||
| Revenue per share | $0.51 | — | — | — | — | — | — | — | — | — |
| Earnings per share | −$1.74 | — | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$0.98 | — | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$0.98 | — | — | — | — | — | — | — | — | — |
| Cash per share | $0.01 | — | — | — | — | — | — | — | — | — |
| Book value per share | $0.41 | — | — | — | — | — | — | — | — | — |
| Tangible book value per share | −$0.90 | — | — | — | — | — | — | — | — | — |
| Capex per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Debt per share | $1.02 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 8.5M | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −271.5% | −188.1% | −29.7% | 30.2% | 18.1% | −19.5% | −22.7% | −7.2% | 221.3% | −38.8% |
| Return on invested capital (ROIC) | −65.9% | −64.7% | −29.4% | 34.8% | 26.9% | −22.7% | −22.6% | −11.9% | −37.3% | −26.8% |
| Return on assets (ROA) | −24.0% | −68.8% | −18.7% | 20.9% | 10.4% | −9.7% | −19.1% | −6.3% | 178.1% | −20.8% |
| Return on tangible assets | −30.3% | −110.7% | −22.6% | 25.1% | 8.6% | −7.3% | −25.6% | −8.4% | 122.5% | −22.4% |
| Free cash flow margin | −192.0% | −272.4% | −32.7% | 20.1% | −22.6% | −29.5% | −10.8% | −17.2% | −30.9% | −5.3% |
| Income quality (OCF / net income) | — | — | — | 1.55 | −2.17 | — | — | — | −0.07 | — |
| Financial health | ||||||||||
| Total debt | $8.6M | $24.6M | $18.5M | $7.0M | $14.9M | $14.7M | $926,000 | $3.6M | $0 | $1.5M |
| Cash & short-term investments | $90,000 | $678,000 | $4.7M | $17.4M | $17.5M | $8.5M | $1.4M | $8.2M | $21.9M | $441,000 |
| Net debt | $8.5M | $23.9M | $13.7M | −$10.5M | −$2.6M | $6.3M | −$434,000 | −$4.7M | −$21.9M | $1.0M |
| Debt / equity | 2.46 | 3.34 | 0.37 | 0.11 | 0.25 | 1.39 | 0.08 | 0.22 | 0.00 | 0.25 |
| Debt / assets | 0.14 | 0.39 | 0.20 | 0.08 | 0.17 | 0.47 | 0.08 | 0.17 | 0.00 | 0.12 |
| Net debt / EBITDA | — | — | — | −0.36 | −0.23 | — | — | — | — | — |
| Current ratio | 0.06 | 0.95 | 2.28 | 3.78 | 3.95 | 2.52 | 10.66 | 4.31 | 15.96 | 1.41 |
| Quick ratio | 0.06 | 0.92 | 2.17 | 3.54 | 3.65 | 2.04 | 9.10 | 3.86 | 15.11 | 1.01 |
| Interest coverage | -2.6 | -11.5 | -17.0 | 30.9 | 8.5 | -13.5 | — | — | -73.9 | -12.5 |
| Working capital | −$49.9M | −$1.5M | $26.7M | $44.8M | $45.8M | $9.6M | $9.0M | $14.0M | $27.1M | $2.8M |
| Invested capital | $12.0M | $31.2M | $63.1M | $53.2M | $56.0M | $16.8M | $10.8M | $11.9M | $9.9M | $7.0M |
| Tangible asset value | −$7.6M | −$7.6M | $31.8M | $49.4M | $42.1M | $8.4M | $11.2M | $16.5M | $33.1M | $6.0M |
| Net current asset value | −$53.2M | −$25.2M | $5.0M | $36.8M | $30.6M | −$5.0M | $8.9M | $14.0M | $27.8M | $2.8M |
| Graham net-net per share | −$6.49 | — | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | $193,000 | $9.4M | $4.5M | $2.9M | $5.8M | $11.7M | $1.5M | $0 |
| Share buybacks (net) | — | $0 | $6.0M | $9.6M | $917,000 | — | — | $0 | $16.3M | $0 |
| Dividend payout ratio | — | — | — | 50.7% | 72.5% | — | — | — | 3.6% | — |
| Dividends + buybacks / free cash flow | — | — | — | 77.1% | — | — | — | — | — | — |
| Capex / revenue | 0.0% | 13.4% | 7.1% | 3.2% | 5.4% | 11.6% | 2.3% | 1.1% | 2.1% | 3.1% |
| Capex / operating cash flow | — | — | — | 13.7% | — | — | — | — | — | — |
| Capex / depreciation | 0.00 | 0.14 | 0.47 | 0.77 | 1.19 | 3.69 | 0.57 | 0.37 | 0.62 | 1.53 |
| Stock-based compensation / revenue | 43.6% | 53.7% | 8.0% | 3.2% | 4.0% | 10.1% | 7.5% | 4.8% | 0.8% | 0.0% |
| R&D / revenue | 2.5% | 8.8% | 3.2% | 0.5% | 0.7% | 4.4% | 3.4% | 3.0% | 4.4% | 2.7% |
| SG&A / revenue | 444.7% | 559.6% | 82.1% | 37.8% | 28.5% | 54.8% | 55.9% | 45.8% | 55.8% | 57.8% |
| Efficiency | ||||||||||
| Days sales outstanding | 907.0 | 1,506.2 | 299.6 | 111.2 | 94.3 | 125.5 | 270.2 | 135.5 | 142.7 | 84.8 |
| Days of inventory on hand | 74.8 | 90.6 | 40.6 | 30.1 | 30.2 | 82.9 | 84.5 | 75.1 | 98.3 | 117.8 |
| Days payables outstanding | 1,644.3 | 589.7 | 94.3 | 45.4 | 42.6 | 77.4 | 21.8 | 21.8 | 62.6 | 52.4 |
| Cash conversion cycle (days) | -662.5 | 1,007.0 | 245.9 | 96.0 | 81.9 | 130.9 | 332.8 | 188.7 | 178.4 | 150.2 |
| Receivables turnover | 0.40 | 0.24 | 1.22 | 3.28 | 3.87 | 2.91 | 1.35 | 2.69 | 2.56 | 4.30 |
| Payables turnover | 0.22 | 0.62 | 3.87 | 8.04 | 8.56 | 4.71 | 16.71 | 16.71 | 5.83 | 6.96 |
| Inventory turnover | 4.88 | 4.03 | 8.98 | 12.13 | 12.10 | 4.41 | 4.32 | 4.86 | 3.71 | 3.10 |
| Asset turnover | 0.07 | 0.09 | 0.49 | 1.39 | 1.31 | 0.66 | 0.60 | 0.48 | 0.42 | 1.52 |
| Average receivables | $10.8M | $27.9M | $36.4M | $37.4M | $20.4M | $5.0M | $7.3M | $4.9M | $3.9M | $4.9M |
| Average payables | $13.3M | $11.2M | $7.3M | $6.5M | $5.4M | $2.1M | $434,500 | $499,500 | $1.4M | $1.6M |
| Average inventory | $606,500 | $1.7M | $3.1M | $4.3M | $3.8M | $2.2M | $1.7M | $1.7M | $2.1M | $3.5M |
| Intangibles / total assets | 18.6% | 23.7% | 19.1% | 16.2% | 18.5% | 6.8% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from PRPH's annual financial statements (latest annual report filed June 1, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PRPH valuation and financial ratios
ProPhase Labs earned a return on equity of −271.5% and a return on invested capital of −65.9% in fiscal 2025. It ended the year with $8.6 million of debt and $0.1 million in cash and short-term investments, net debt of $8.5 million.
See the PRPH income statement, the PRPH chart for price history, or the PRPH stock overview for the latest quote and news.
PRPH key metrics FAQ
What is ProPhase Labs's return on equity?
ProPhase Labs's return on equity (ROE) was −271.5% in fiscal 2025: net income of -$14.7 million on average shareholders' equity of $5.4 million.
What is ProPhase Labs's ROIC?
ProPhase Labs's return on invested capital was −65.9% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does ProPhase Labs have?
ProPhase Labs had total debt of $8.6 million at the end of fiscal 2025, a debt-to-equity ratio of 2.46.
What is ProPhase Labs's free cash flow yield?
ProPhase Labs generated -$8.3 million of free cash flow in fiscal 2025, a free cash flow yield of −219.6% on its market value at year-end ($3.8 million).
What is ProPhase Labs's current ratio?
ProPhase Labs's current ratio was 0.06 at the end of fiscal 2025: current assets were 0.06 times current liabilities.